Prostate cancer vaccines: Maximizing a suboptimal immune response for improved outcome Journal Article
| Author: | Slovin, S. F. |
| Article Title: | Prostate cancer vaccines: Maximizing a suboptimal immune response for improved outcome |
| Abstract: | As approaches toward isolating tumor-associated antigens have become more refined, vaccines composed of novel cell surface proteins, peptides, or DNA encoding the molecule of interest have been developed. All of these approaches have in some way been shown to break immunologic tolerance, either by the generation of high-titer antibodies against the immunogen or by eliciting T-cell responses as shown by T-cell proliferation assays or specific cytokine release via enzyme-linked immunosorbent spot. No single immunologic approach to date has successfully shown significant durable disease remission in prostate cancer, albeit clinical trials using immune modulators together with vaccines have suggested that radiographic antitumor responses are feasible. This review updates the status of prostate cancer vaccines as tools for induction of active immunity and discusses the issues relevant to their clinical trial development. |
| Keywords: | survival; treatment outcome; survival analysis; unclassified drug; overall survival; prednisone; clinical trial; disease course; review; placebo; multimodality cancer therapy; antineoplastic agents; clinical trials as topic; combined modality therapy; methodology; antineoplastic agent; lymphocyte proliferation; t lymphocyte; t-lymphocytes; prostate specific antigen; cytotoxic t lymphocyte antigen 4 antibody; dendritic cell vaccine; ipilimumab; unindexed drug; interleukin 4; tumor antigen; viral gene delivery system; docetaxel; drug dose escalation; fever; prostate cancer; prostatic neoplasms; cancer regression; cytokine; immunological tolerance; immunology; prostate specific membrane antigen; rigor; cellular immunity; immune response; antigens, neoplasm; gamma interferon; immunoglobulin g; cancer vaccine; cancer vaccines; disease progression; antigen detection; prostate tumor; vaccination; psa; vaccinia virus; tumor immunity; cytokine production; adenovirus vector; mucin 1; ctla-4; antigens, cd; virus recombinant; provenge; cytotoxic t lymphocyte antigen 4; granulocyte macrophage colony stimulating factor vaccine; cytokine release; enzyme linked immunospot assay; humoral immunity; antibody; leukocyte antigen; prostate stem cell antigen; plasmid vector; drug delivery system; vaccines; antigens, differentiation; antibody titer; keyhole limpet hemocyanin; cell surface protein; immunoglobulin m; differentiation antigen; carbon dioxide; nonviral gene delivery system; poxvirus; cancer antibody; mucin 2; t cell; leukapheresis; cytotoxic t-lymphocyte antigen 4; major histocompatibility antigen; active immunization; sipuleucel t; acid phosphatase prostate isoenzyme |
| Journal Title: | Clinical Advances in Hematology & Oncology |
| Volume: | 5 |
| Issue: | 12 |
| ISSN: | 1543-0790 |
| Publisher: | Millennium Medical Publishing, Inc |
| Date Published: | 2007-12-01 |
| Start Page: | 972 |
| End Page: | 984 |
| Language: | English |
| PUBMED: | 18277959 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 1" - "Export Date: 17 November 2011" - "Source: Scopus" |
